DexCom (DXCM) Competitors $75.88 +1.20 (+1.61%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DXCM vs. ABMD, TFX, MDT, BDX, EW, RMD, IDXX, STE, PODD, and HOLXShould you be buying DexCom stock or one of its competitors? The main competitors of DexCom include Abiomed (ABMD), Teleflex (TFX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), STERIS (STE), Insulet (PODD), and Hologic (HOLX). These companies are all part of the "health care equipment" industry. DexCom vs. Abiomed Teleflex Medtronic Becton, Dickinson and Company Edwards Lifesciences ResMed IDEXX Laboratories STERIS Insulet Hologic Abiomed (NASDAQ:ABMD) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Do analysts prefer ABMD or DXCM? DexCom has a consensus target price of $104.59, indicating a potential upside of 37.83%. Given DexCom's stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Abiomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abiomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00DexCom 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.72 Which has higher valuation and earnings, ABMD or DXCM? DexCom has higher revenue and earnings than Abiomed. DexCom is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbiomed$1.03B16.65$136.51M$5.8265.47DexCom$3.95B7.50$541.50M$1.6745.44 Does the media favor ABMD or DXCM? In the previous week, DexCom had 20 more articles in the media than Abiomed. MarketBeat recorded 20 mentions for DexCom and 0 mentions for Abiomed. DexCom's average media sentiment score of 1.24 beat Abiomed's score of 0.44 indicating that DexCom is being referred to more favorably in the news media. Company Overall Sentiment Abiomed Neutral DexCom Positive Is ABMD or DXCM more profitable? Abiomed has a net margin of 24.84% compared to DexCom's net margin of 17.22%. DexCom's return on equity of 31.40% beat Abiomed's return on equity.Company Net Margins Return on Equity Return on Assets Abiomed24.84% 14.77% 13.32% DexCom 17.22%31.40%10.58% Does the MarketBeat Community prefer ABMD or DXCM? DexCom received 436 more outperform votes than Abiomed when rated by MarketBeat users. Likewise, 71.66% of users gave DexCom an outperform vote while only 60.52% of users gave Abiomed an outperform vote. CompanyUnderperformOutperformAbiomedOutperform Votes53560.52% Underperform Votes34939.48% DexComOutperform Votes97171.66% Underperform Votes38428.34% Which has more risk and volatility, ABMD or DXCM? Abiomed has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Do institutionals & insiders hold more shares of ABMD or DXCM? 94.5% of Abiomed shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 2.5% of Abiomed shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryDexCom beats Abiomed on 12 of the 19 factors compared between the two stocks. Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Get DexCom News Delivered to You Automatically Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXCM vs. The Competition Export to ExcelMetricDexComSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.64B$4.56B$5.06B$8.66BDividend YieldN/A39.56%5.09%4.06%P/E Ratio45.4425.28101.8517.37Price / Sales7.5055.051,196.8169.07Price / Cash35.0551.7440.9136.36Price / Book14.975.486.335.87Net Income$541.50M$13.76M$119.64M$225.66M7 Day Performance8.46%-6.52%-5.12%-1.34%1 Month Performance8.56%1.37%-3.21%1.00%1 Year Performance-27.57%50.40%32.52%25.27% DexCom Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXCMDexCom4.9789 of 5 stars$75.88+1.6%$104.59+37.8%-27.6%$29.64B$3.95B45.449,600Short Interest ↑Positive NewsABMDAbiomedN/A$381.02flatN/A+0.0%$17.18B$1.03B65.472,003Analyst ForecastTFXTeleflex4.9107 of 5 stars$195.58-1.2%N/A-10.1%$9.08B$3.03B38.8814,500Analyst UpgradeMDTMedtronic4.8623 of 5 stars$88.250.0%N/A+16.9%$113.18B$32.58B29.8195,000Upcoming EarningsAnalyst ForecastNews CoverageBDXBecton, Dickinson and Company4.9898 of 5 stars$231.26-1.4%N/A-4.2%$66.84B$20.18B38.9373,000Short Interest ↓EWEdwards Lifesciences4.5508 of 5 stars$65.81-1.3%N/A+0.4%$38.81B$6.00B9.5019,800Insider SellingShort Interest ↓Analyst RevisionRMDResMed4.7261 of 5 stars$247.11-0.6%N/A+57.6%$36.27B$4.81B32.739,980Insider SellingAnalyst RevisionNews CoveragePositive NewsIDXXIDEXX Laboratories4.8773 of 5 stars$426.11-2.6%N/A-9.8%$34.89B$3.84B41.0911,000Options VolumePositive NewsSTESTERIS4.953 of 5 stars$222.73+0.4%N/A+8.2%$21.96B$5.33B50.8518,179Short Interest ↓PODDInsulet4.4023 of 5 stars$275.10-0.2%N/A+48.8%$19.29B$1.98B47.113,000Analyst RevisionHOLXHologic4.8746 of 5 stars$79.76+0.5%N/A+8.2%$18.53B$4.03B23.956,990Analyst UpgradeShort Interest ↓Analyst RevisionNews Coverage Related Companies and Tools Related Companies Abiomed Competitors Teleflex Competitors Medtronic Competitors Becton, Dickinson and Company Competitors Edwards Lifesciences Competitors ResMed Competitors IDEXX Laboratories Competitors STERIS Competitors Insulet Competitors Hologic Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DXCM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DXCM Stock Alerts